department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Raltegravir · pharmadog

pharmadog
drugs
Raltegravir

drug

patient view →

raltegravir potassium

Marketedupdated 2mo ago

by Lupin Ltd

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Raltegravir

generic

raltegravir potassium

indication

Human Immunodeficiency Virus (HIV) Infections (AIDS)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 28, 2028

~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (17)

Mar 30, 2032method-of-use (U-1663)US 10772888
Apr 21, 2031patentUS 9649311*PED4.8y
Oct 21, 2030formulationUS 96493114.3y
Jun 2, 2030compositionUS 87717333.9y
Jun 2, 2030compositionUS 87717333.9y
Jun 2, 2030compositionUS 87717333.9y
Sep 11, 2029patentUS 7754731*PED3.2y
Sep 11, 2029patentUS 7754731*PED3.2y
Sep 11, 2029patentUS 7754731*PED3.2y
Sep 11, 2029patentUS 7754731*PED3.2y
Sep 11, 2029patentUS 7754731*PED3.2y
Mar 11, 2029compositionUS 77547312.7y
Mar 11, 2029compositionUS 77547312.7y
Mar 11, 2029compositionUS 77547312.7y
Mar 11, 2029compositionUS 77547312.7y
Mar 11, 2029compositionUS 77547312.7y
Jan 28, 2028compositionUS 88526321.6y

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying raltegravir potassium

phase3Renal Transplantation and Raltegravir in HIV-Infected Patientscompletedn=27
phase2Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipientscompletedn=14
phase2Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRALcompletedn=170
phase2Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patientscompletedn=30
phase2Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophyterminatedn=48
phase4A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimencompletedn=558
phase3Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDYcompletedn=61
phase4Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patientscompletedn=10

more trials →